As participações na receita são estimativas para year ended 2025-12-31, high confidence, não números de um relatório oficial.
Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.
ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.
Demonstrações financeiras completas →
Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.
Construído a partir dos próprios documentos de Amgen Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
US$ 465,73-0,3%fechamento 13 de nov.
Números até 30 de setembro de 2026, do 10-Q arquivado em 4 de novembro de 2026
Amgen discovers, makes and sells prescription medicines for serious diseases, along with biosimilar medicines.
Projeção da empresa: receita de de US$ 38,9B a US$ 39,7B para Ano fiscal 2026 — alta de 6,9% em relação ao ano anterior
Just reported
From Amgen's results release of 3 de novembro de 2026; its quarterly report has since been filed.
Actual
US$ 10,37B
+8,5% y/y
+3,1% q/q
Guided
—
No guide given
Actual
US$ 7,08
+19% y/y
+62% q/q
Guided
—
No guide given
Actual
US$ 3,71B
+47% y/y
+5,6% q/q
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade A+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Amgen Inc.. Os outros 39 vão até outubro de 2016.
